209 related articles for article (PubMed ID: 33600609)
1. Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda S; Heimann A; Obermayer B; Ciraolo E; Althoff S; Ruß J; Grunert C; Busse A; Bullinger L; Pezzutto A; Blankenstein T; Beule D; Na IK
Int J Cancer; 2021 Jun; 148(12):3097-3110. PubMed ID: 33600609
[TBL] [Abstract][Full Text] [Related]
2. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
3. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
5. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
Kaartinen T; Luostarinen A; Maliniemi P; Keto J; Arvas M; Belt H; Koponen J; Mäkinen PI; Loskog A; Mustjoki S; Porkka K; Ylä-Herttuala S; Korhonen M
Cytotherapy; 2017 Jun; 19(6):689-702. PubMed ID: 28411126
[TBL] [Abstract][Full Text] [Related]
6. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
Daudt L; Maccario R; Locatelli F; Turin I; Silla L; Montini E; Percivalle E; Giugliani R; Avanzini MA; Moretta A; Montagna D
J Immunother; 2008 May; 31(4):385-93. PubMed ID: 18391757
[TBL] [Abstract][Full Text] [Related]
9. Antigen-specific CD8+ memory stem T cells generated from human peripheral blood effectively eradicate allogeneic targets in mice.
Guan L; Li X; Wei J; Liang Z; Yang J; Weng X; Wu X
Stem Cell Res Ther; 2018 Dec; 9(1):337. PubMed ID: 30526661
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Manufacturing Protocols Enriching T
Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
Front Immunol; 2020; 11():1217. PubMed ID: 32636841
[TBL] [Abstract][Full Text] [Related]
11. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.
Petersen CT; Hassan M; Morris AB; Jeffery J; Lee K; Jagirdar N; Staton AD; Raikar SS; Spencer HT; Sulchek T; Flowers CR; Waller EK
Blood Adv; 2018 Feb; 2(3):210-223. PubMed ID: 29386194
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
13. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells.
Caserta S; Alessi P; Basso V; Mondino A
Eur J Immunol; 2010 Feb; 40(2):470-9. PubMed ID: 19950184
[TBL] [Abstract][Full Text] [Related]
14. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
Front Immunol; 2020; 11():482. PubMed ID: 32528460
[TBL] [Abstract][Full Text] [Related]
15. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
[TBL] [Abstract][Full Text] [Related]
16.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
17. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
18. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
20. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
